January 2022 - QuartzBio

Title: Keeping Track of Clinical Samples in Biomarker-Rich Clinical Trials

Duration: 30 minutes

Learn how clinical operations and translational teams are creating “sponsor-centric” visibility to reconcile sample status and location on-study.

PRESENTATION: “30 Days to an Annotated Virtual Repository — Without Changing DTAs”

Clinical and biomarker operations teams can create ongoing visibility into sample collection, processing and testing by linking biospecimen metadata, informed consent, and biomarker data across multiple LIMS and inventories.
Mike Waters will share how teams are using technology to access a single source of truth for sample inventory management.

January 10, 2022 — With immuno-oncology assets progressing in the clinic, a growing biotechnology company we work with faces an increasingly common challenge:

Their trials are generating large datasets across a wide range of assay modalities (Figure 1), but the data remains siloed.

In addition to clinical data coming from the clinical research organization (CRO), the velocity of data coming from an assay services laboratory continuously delivering biomarker data from flow cytometry, immunohistochemistry, and genomics platforms quickly becomes overwhelming. Still another, separate data stream comes from a specialty laboratory delivering T-cell receptor (TCR) profiling data.